ObsEva SA (NASDAQ:OBSV) has earned an average rating of “Buy” from the six brokerages that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $23.25.

OBSV has been the topic of several research analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $27.00 price objective on shares of ObsEva SA in a research note on Friday, September 8th. Zacks Investment Research lowered ObsEva SA from a “hold” rating to a “sell” rating in a research note on Saturday, August 19th. Royal Bank Of Canada initiated coverage on ObsEva SA in a research note on Thursday. They issued an “outperform” rating on the stock. Finally, Leerink Swann reaffirmed an “outperform” rating and issued a $18.00 price objective on shares of ObsEva SA in a research note on Wednesday, August 16th.

ILLEGAL ACTIVITY WARNING: “ObsEva SA (OBSV) Given Consensus Recommendation of “Buy” by Brokerages” was first published by American Banking News and is the property of of American Banking News. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The correct version of this article can be read at https://www.americanbankingnews.com/2017/09/14/obseva-sa-obsv-given-consensus-recommendation-of-buy-by-brokerages.html.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. NEA Management Company LLC acquired a new position in shares of ObsEva SA in the 1st quarter valued at about $34,734,000. Sphera Funds Management LTD. lifted its position in ObsEva SA by 9.7% during the 2nd quarter. Sphera Funds Management LTD. now owns 231,497 shares of the company’s stock worth $1,979,000 after acquiring an additional 20,411 shares in the last quarter. Sectoral Asset Management Inc lifted its position in ObsEva SA by 181.9% during the 2nd quarter. Sectoral Asset Management Inc now owns 212,831 shares of the company’s stock worth $1,820,000 after acquiring an additional 137,331 shares in the last quarter. VHCP Management II LLC acquired a new position in ObsEva SA during the 2nd quarter worth approximately $1,283,000. Finally, UBS Oconnor LLC acquired a new position in ObsEva SA during the 1st quarter worth approximately $1,017,000. 48.46% of the stock is currently owned by institutional investors and hedge funds.

Shares of ObsEva SA (OBSV) traded down 0.28% during mid-day trading on Thursday, reaching $7.05. 12,055 shares of the company’s stock were exchanged. The stock has a 50 day moving average price of $6.96 and a 200 day moving average price of $10.41. ObsEva SA has a 52 week low of $6.77 and a 52 week high of $14.18. The stock’s market cap is $200.90 million.

ObsEva SA (NASDAQ:OBSV) last released its quarterly earnings data on Tuesday, August 15th. The company reported ($0.61) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.13). During the same quarter last year, the business earned ($0.30) earnings per share. Equities research analysts predict that ObsEva SA will post ($2.32) EPS for the current year.

About ObsEva SA

Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109 is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and blocks the endogenous GnRH from activating its pituitary receptors, which reduces estrogen production by the ovaries and leads to amenorrhea.

Analyst Recommendations for ObsEva SA (NASDAQ:OBSV)

Receive News & Ratings for ObsEva SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva SA and related companies with MarketBeat.com's FREE daily email newsletter.